|
1.
|
|
12 p, 1.1 MB |
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL : primary analysis of the CAPTIVATE FD cohort
/
Tam, Constantine S (University of Melbourne) ;
Allan, John N (Weill Cornell Medicine) ;
Siddiqi, Tanya (City of Hope National Medical Center) ;
Kipps, Thomas J. (University of California San Diego) ;
Jacobs, Ryan (Levine Cancer Institute) ;
Opat, Stephen (Monash University) ;
Barr, Paul M. (University of Rochester Medical Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Trentin, Livio (University of Padova) ;
Bannerji, Rajat (Rutgers Cancer Institute of New Jersey) ;
Jackson, Sharon (Middlemore Hospital) ;
Kuss, Bryone J. (Flinders University and Medical Center) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Szafer-Glusman, Edith (Pharmacyclics LLC. an AbbVie Company) ;
Russell, Kristin (Pharmacyclics LLC. an AbbVie Company) ;
Zhou, Cathy (Pharmacyclics LLC. an AbbVie Company) ;
Ninomoto, Joi (Pharmacyclics LLC. an AbbVie Company) ;
Dean, James P. (Pharmacyclics LLC. an AbbVie Company) ;
Wierda, William G. (DepaUniversity of Texas MD Anderson Cancer Center) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. [...]
2022 -  10.1182/blood.2021014488
Blood, Vol. 139 Núm. 22 (february 2022) , p. 3278-3289
|
|
|
2.
|
|
11 p, 1.9 MB |
Many people with chronic lymphocytic leukemia or small lymphocytic lymphoma benefit from ibrutinib treatment up to 8 years : a plain language summary
/
Barr, Paul M. (University of Rochester Medical Center, USA) ;
Owen, Carolyn (University of Calgary, Canada) ;
Robak, Tadeusz (Medical University of Lodz, Copernicus Memorial Hospital, Lodz, Poland) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy) ;
Bairey, Osnat (Rabin Medical Center, Petah Tikva, Israel) ;
Burger, Jan A (University of Texas MD Anderson Cancer Center, Houston, USA) ;
Hillmen, Peter (The Leeds Teaching Hospitals, St James Institute of Oncology, Leeds, UK) ;
Dearden, Claire (The Royal Marsden Hospital, London, UK) ;
Grosicki, Sebastian (Silesian Medical University, Katowice, Poland) ;
McCarthy, Helen (Royal Bournemouth General Hospital (Dorset, Regne Unit)) ;
Li, Jian Yong (Jiangsu Province Hospital, Nanjing, China) ;
Offner, Fritz (Universitair Ziekenhuis Gent, Belgium) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Jermain, Mandy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Zhou, Cathy (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Hsu, Emily (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Szoke, Anita (Pharmacyclics LLC, an AbbVie Company, South San Francisco, USA) ;
Kipps, Thomas J. (UCSD Moores Cancer Center, San Diego, USA) ;
Ghia, Paolo (Università Vita-Salute San Raffaele &IRCCS Ospedale San Raffaele, Milan, Italy)
What is this summary about? This is a plain language summary of a publication describing long-term results from the RESONATE-2 study with up to 8 years of follow-up. The original paper was published in Blood Advances in June 2022. [...]
2022 - 10.2217/fon-2022-0898
Future oncology (London, England), Vol. 18 Núm. 37 (january 2022)
|
|
|
3.
|
|
9 p, 442.2 KB |
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib Therapy
/
Woyach, Jennifer A. (The Ohio State University Comprehensive Cancer Center, Columbus, Ohio) ;
Ghia, Paolo (Universita Vita-Salute San Raffaele, Milan, Italy) ;
Byrd, John C. (University of Cincinnati College of Medicine, Cincinnati, Ohio) ;
Ahn, Inhye E. (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Brien, Susan M. (UC Irvine. Chao Family Comprehensive Cancer Center, Irvine, California) ;
Jones, Daniel (The Ohio State University Comprehensive Cancer Center, Irvine, California) ;
Cheung, Leo W.K. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Chong, Elizabeth (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Kwei, Kevin (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Dean, James P. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
James, Dannelle F. (Pharmacyclics LLC, an AbbVie Company, South San Francisco, California) ;
Wiestner, Adrian (Laboratory of Lymphoid Malignancies, National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland)
Purpose: Acquired mutations in Bruton's tyrosine kinase (BTK) or phospholipase C-γ2 (PLCG2) genes are associated with clinical progressive disease (PD) in patients with chronic lymphocytic leukemia (CLL) treated with BTK inhibitors. [...]
2023 - 10.1158/1078-0432.CCR-22-3887
Clinical Cancer Research, Vol. 29 Núm. 16 (august 2023) , p. 3065-3073
|
|
|
4.
|
|
16 p, 3.8 MB |
Genetic and phenotypic attributes of splenic marginal zone lymphoma
/
Bonfiglio, Ferdinando (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bruscaggin, Alessio (Institute of Oncology Research, Bellinzona, Switzerland) ;
Guidetti, Francesca (Institute of Oncology Research, Bellinzona, Switzerland) ;
Terzi di Bergamo, Lodovico (Institute of Oncology Research, Bellinzona, Switzerland) ;
Faderl, Martin (Institute of Oncology Research, Bellinzona, Switzerland) ;
Spina, Valeria (Institute of Oncology Research, Bellinzona, Switzerland) ;
Condoluci, Adalgisa (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bonomini, Luisella (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ;
Forestieri, Gabriela (Institute of Oncology Research, Bellinzona, Switzerland) ;
Koch, Ricardo (Institute of Oncology Research, Bellinzona, Switzerland) ;
Piffaretti, Deborah (Institute of Oncology Research, Bellinzona, Switzerland) ;
Pini, Katia (Institute of Oncology Research, Bellinzona, Switzerland) ;
Pirosa, Maria Cristina (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Cittone, Micol Giulia (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Arribas, Alberto (Lymphoma Genomics, Institute of Oncology Research, Bellinzona, Switzerland) ;
Lucioni, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy) ;
Ghilardi, Guido (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.) ;
Wu, Wei (Institute of Oncology Research, Bellinzona, Switzerland) ;
Arcaini, Luca (University of Pavia, Pavia, Italy.) ;
Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Bastidas-Mora, Gabriela (Hospital Clínic i Provincial de Barcelona) ;
Bea, Sílvia (Hospital Clínic i Provincial de Barcelona) ;
Boldorini, Renzo (University of Eastern Piedmont, Novara, Italy) ;
Broccoli, Alessandro (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.) ;
Buehler, Marco Matteo (University Hospital Zurich, Switzerland) ;
Canzonieri, Vincenzo (Pathology Unit, CRO Aviano National Cancer Institute, Aviano, Italy) ;
Cascione, Luciano (Institute of Oncology Research, Bellinzona, Switzerland) ;
Ceriani, Luca (Clinic of Nuclear Medicine and PET-CT Centre, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Cogliatti, Sergio (Institute of Pathology, Kantonsspital St Gallen, St Gallen, Switzerland) ;
Corradini, Paolo (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) ;
Derenzini, Enrico (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ;
Devizzi, Liliana (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ;
Dietrich, Sascha (University Hospital Heidelberg, Germany) ;
Elia, Angela Rita (Institute of Oncology Research, Bellinzona, Switzerland) ;
Facchetti, Fabio (Pathology Unit, Spedali Civili, Brescia, Italy) ;
Gaidano, Gianluca (University of Eastern Piedmont, Novara, Italy) ;
Garcia, Juan Fernando (MD Anderson Cancer Center, Madrid) ;
Gerber, Bernhard (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ;
Gomes da Silva, Maria (Instituto Português de Oncologia de Lisboa, Portugal) ;
Gritti, Giuseppe (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ;
Guidetti, Anna (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ;
Hitz, Felicitas (Kantonsspital St Gallen, St Gallen, Switzerland) ;
Inghirami, Giorgio (Weill Cornell Medical College, New York) ;
Ladetto, Marco (Azienda Ospedaliera SS Antonio e Biagio, Alessandria, Italy) ;
Lopez-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Lucchini, Elisa (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ;
Maiorana, Antonino (Universitá degli Studi di Modena e Reggio Emilia, Modena, Italy) ;
Marasca, Roberto (University of Modena and Reggio Emilia, Modena, Italy) ;
Matutes, Estella (Hospital Clínic i Provincial de Barcelona) ;
Meignin, Veronique (Saint Louis Hospital, Paris, France) ;
Merli, Michele (University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy) ;
Moccia, Alden (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Mollejo, Manuela (Hospital Virgen de la Salud (Toledo)) ;
Montalban, Carlos (MD Anderson Cancer Center, Madrid) ;
Novak, Urban (University of Bern, Bern, Switzerland) ;
Oscier, David Graham (University Hospitals Dorset, Bournemouth, United Kingdom) ;
Passamonti, Francesco (University of Insubria) ;
Piazza, Francesco (Ospedale Universitario di Padova, Italy) ;
Pizzolitto, Stefano (General Hospital S Maria della Misericordia, Udine, Italy) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ;
Sabattini, Elena (University of Bologna, Italy) ;
Salles, Gilles (Université de Lyon, France) ;
Santambrogio, Elisa (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ;
Scarfò, Lydia (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ;
Stathis, Anastasios (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Stüssi, Georg (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Geyer, Julia T. (Weill Cornell Medical College, New York) ;
Tapia, G. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Tarella, Corrado (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ;
Thieblemont, Catherine (Université de Paris, France) ;
Tousseyn, Thomas (University Hospitals Leuven, Belgium) ;
Tucci, Alessandra (Spedali Civili, Brescia, Italy.) ;
Vanini, Giorgio (University of Bern, Switzerland) ;
Visco, Carlo (University of Verona, Italy) ;
Vitolo, Umberto (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ;
Walewska, Renata (University Hospitals Dorset, Bournemouth, United Kingdom) ;
Zaja, Francesco (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ;
Zenz, Thorsten (University Hospital Zurich, Switzerland) ;
Zinzani, Pier Luigi (Università di Bologna, Italy) ;
Khiabanian, Hossein (Rutgers University, New Brunswick) ;
Calcinotto, Arianna (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bertoni, Francesco (Institute of Oncology Research, Bellinzona, Switzerland) ;
Bhagat, Govind (Columbia University, New York, USA) ;
Campo, Elias (Hospital Clínic i Provincial de Barcelona) ;
de Leval, Laurence (Institut Universitaire de Pathologie, Lausanne, Switzerland) ;
Dirnhofer, Stefan (University Hospital Basel (Basilea, Suïssa)) ;
Pileri, Stefano A. (European Institute of Oncology IRCCS, Milan, Italy) ;
Piris, Miguel Angel (Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid) ;
Traverse-Glehen, Alexandra (Centre Hospitalier Lyon Sud, Lyon, France) ;
Tzankov, Alexander (University Hospital Basel (Basilea, Suïssa)) ;
Paulli, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Italy) ;
Ponzoni, Maurilio (Ateneo Vita-Salute San Raffaele University and Pathology Unit San Raffaele Scientific Institute, Milan, Italy) ;
Mazzucchelli, Luca (antonal Institute of Pathology, Locarno, Switzerland) ;
Cavalli, Franco (Institute of Oncology Research, Bellinzona, Switzerland; and.) ;
Zucca, Emanuele (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ;
Rossi, Davide (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ;
Universitat Autònoma de Barcelona
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. [...]
2022 - 10.1182/blood.2021012386
Blood, Vol. 139 Núm. 5 (february 2022) , p. 732-747
|
|
|
5.
|
|
8 p, 393.1 KB |
Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry : An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project
/
Rawstron, Andy C. (St. James's Institute of Oncology) ;
Kreuzer, Karl-Anton (Universitätsklinikum Köln) ;
Soosapilla, Asha (Laverty Pathology) ;
Spacek, Martin (University Hospital) ;
Stehlikova, Olga (University Hospital Brno (República Txeca)) ;
Gambell, Peter (Peter MacCallum Cancer Centre) ;
McIver-Brown, Neil (Royal Bournemouth Hospital) ;
Villamor, Neus (Hospital Clínic i Provincial de Barcelona) ;
Psarra, Katherina (Evangelismos Hospital) ;
Arroz, Maria (C.H.L.O. Hospital S. Francisco Xavier) ;
Milani, Raffaella (Ospedale San Raffaele) ;
de la Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Cedena, M.Teresa (Hospital 12 de Octubre (Madrid)) ;
Jaksic, Ozren (Dubrava University Hospital) ;
Nomdedeu, Josep (Institut d'Investigació Biomèdica Sant Pau) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Rigolin, Gian Matteo (St. Anna University Hospital) ;
Cuneo, Antonio (St. Anna University Hospital) ;
Johansen, Preben (Aalborg Universitet) ;
Johnsen, Hans E. (Aalborg Universitet) ;
Rosenquist, Richard (Uppsala University) ;
Niemann, Carsten Utoft (Copenhagen University Hospital) ;
Kern, Wolfgang (MLL Munich Leukemia Laboratory) ;
Westerman, David (University Hospital Brno (República Txeca)) ;
Trneny, Marek (University Hospital) ;
Mulligan, Stephen (Laverty Pathology) ;
Doubek, Michael (Masaryk University) ;
Pospisilova, Sarka (Masaryk University) ;
Hillmen, Peter (St. James's Institute of Oncology) ;
Oscier, David (Royal Bournemouth Hospital) ;
Hallek, Michael (Universitätsklinikum Köln) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Montserrat, Emili (Hospital Clínic i Provincial de Barcelona) ;
Universitat Autònoma de Barcelona
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. [...]
2018 - 10.1002/cyto.b.21595
Cytometry Part B - Clinical Cytometry, Vol. 94 Núm. 1 (january 2018) , p. 121-128
|
|
|
6.
|
|
9 p, 996.2 KB |
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia : Extended phase 3 results from RESONATE-2
/
Barr, Paul M. (University of Rochester) ;
Robak, Tadeusz (Medical University of Lodz) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Sackler Faculty of Medicine. Tel Aviv University) ;
Bartlett, Nancy L. (Washington University School of Medicine) ;
Burger, Jan A. (University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Devereux, Stephen (Kings College Hospital) ;
Grosicki, Sebastian (School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Li, Jianyong (Jiangsu Province Hospital) ;
Simpson, David (North Shore Hospital) ;
Offner, Fritz (Universitair Ziekenhuis Gent) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Cathy (Pharmacyclics. LLC an AbbVie Company) ;
Styles, Lori (Pharmacyclics. LLC an AbbVie Company) ;
James, Danelle (Pharmacyclics. LLC an AbbVie Company) ;
Kipps, Thomas J (University of California,San Diego. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Results of RESONATE-2 (PCYC-1115/1116) supported approval of ibrutinib for first-line treatment of chronic lymphocytic Rleukemia. Extended analysis of RESONATE-2 was conducted to determine long-term efficacy and safety of ibrutinib in older patients with chronic lymphocytic leukemia. [...]
2018 - 10.3324/haematol.2018.192328
Haematologica, Vol. 103 Núm. 9 (31 2018) , p. 1502-1510
|
|
|
7.
|
|
9 p, 698.5 KB |
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib : A GIMEMA, ERIC and UK CLL FORUM study
/
Cuneo, Antonio (St. Anna University Hospital) ;
Follows, George (Cambridge University Hospitals NHS Foundation Trust (Anglaterra)) ;
Rigolin, Gian Matteo (St. Anna University Hospital) ;
Piciocchi, Alfonso (Italian Group for Adult Hematologic Diseases (GIMEMA)) ;
Tedeschi, Alessandra (Niguarda Cancer Center) ;
Trentin, Livio (University of Padua) ;
Perez, Angeles Medina (Hospital Costa del Sol (Marbella)) ;
Coscia, Marta (University of Turin) ;
Laurenti, Luca (Policlinico A. Gemelli) ;
Musuraca, Gerardo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)) ;
Farina, Lucia (Fondazione IRCCS Istituto Nazionale Tumori) ;
Delgado, Alfredo Rivas (Hospital Clínic i Provincial de Barcelona) ;
Orlandi, Ester Maria (Fondazione IRCCS Policlinico San Matteo) ;
Galieni, Piero (Ospedale C. e G. Mazzoni) ;
Mauro, Francesca Romana ("Sapienza" University) ;
Visco, Carlo (San Bortolo Hospital) ;
Amendola, Angela (San Carlo Hospital) ;
Billio, Atto (Azienda Sanitaria dell'Alto Adige) ;
Marasca, Roberto (University of Modena and Reggio Emilia) ;
Chiarenza, Annalisa (Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele) ;
Meneghini, Vittorio (University Hospital) ;
Ilariucci, Fiorella (Arcispedale S. Maria Nuova) ;
Marchetti, Monia (Cardinal Massaia Hospital) ;
Molica, Stefano (Azienda Ospedaliera Pugliese Ciaccio) ;
Re, Francesca (University Hospital) ;
Gaidano, Gianluca (Università del Piemonte Orientale Amedeo Avogadro) ;
Gonzalez, Marcos (Hospital Universitari IBSAL i CIBERONC) ;
Forconi, Francesco (University Hospital National Health Service Trust) ;
Ciolli, Stefania (Careggi Hospital) ;
Cortelezzi, Agostino (University of Milan) ;
Montillo, Marco (Niguarda Cancer Center) ;
Smolej, Lukas (University Hospital) ;
Schuh, Anna (Oxford University Hospitals NHS Foundation Trust) ;
Eyre, Toby A. (Oxford University Hospitals NHS Foundation Trust) ;
Kennedy, Ben (University Hospitals of Leicester NHS Trust) ;
Bowles, Kris M. (Norwich Medical School) ;
Vignetti, Marco (Italian Group for Adult Hematologic Diseases (GIMEMA)) ;
De La Serna, Javier (Hospital 12 de Octubre (Madrid)) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Foà, Robin ("Sapienza" University) ;
Ghia, Paolo (IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University) ;
Universitat Autònoma de Barcelona
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. [...]
2018 - 10.3324/haematol.2018.189837
Haematologica, Vol. 103 Núm. 7 (march 2018) , p. 1209-1217
|
|
|
8.
|
|
9 p, 1.3 MB |
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia : A cross-trial comparison of phase 3 studies
/
Robak, Tadeusz (Medical University of Lodz) ;
Burger, Jan A. (The University of Texas MD Anderson Cancer Center) ;
Tedeschi, Alessandra (ASST Grande Ospedale Metropolitano Niguarda) ;
Barr, Paul M. (University of Rochester Cancer Center) ;
Owen, Carolyn (University of Calgary) ;
Bairey, Osnat (Tel Aviv University) ;
Hillmen, Peter (St. James's Institute of Oncology) ;
Simpson, David (North Shore Hospital) ;
Grosicki, Sebastian (Silesian Medical University) ;
Devereux, Stephen (King's College Hospital NHS Foundation Trust) ;
McCarthy, Helen (Royal Bournemouth Hospital) ;
Coutre, Steven E (Stanford University School of Medicine) ;
Quach, Hang (St. Vincent's Hospital) ;
Gaidano, Gianluca (Amedeo Avogadro University of Eastern Piedmont) ;
Maslyak, Zvenyslava (Institute of Blood Pathology and Transfusion Medicine of the Academy of Medical Sciences of Ukraine) ;
Stevens, Don A. (Norton Cancer Institute) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Gill, Devinder S. (Princess Alexandra Hospital) ;
Flinn, Ian W. (Sarah Cannon Research Institute/Tennessee Oncology) ;
Gribben, John G. (Queen Mary University of London) ;
Mokatrin, Ahmad (Pharmacyclics LLC. an AbbVie Company) ;
Cheng, Mei (Pharmacyclics LLC. an AbbVie Company) ;
Styles, Lori (Pharmacyclics LLC. an AbbVie Company) ;
James, Danelle F. (Pharmacyclics LLC. an AbbVie Company) ;
Kipps, Thomas J (University of California San Diego) ;
Ghia, Paolo (Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele) ;
Universitat Autònoma de Barcelona
Chemoimmunotherapy (CIT) and targeted therapy with single-agent ibrutinib are both recommended first-line treatments for chronic lymphocytic leukemia (CLL), although their outcomes have not been directly compared. [...]
2018 - 10.1002/ajh.25259
American Journal of Hematology, Vol. 93 Núm. 11 (november 2018) , p. 1402-1410
|
|
|
9.
|
|
18 p, 2.5 MB |
The EHA Research Roadmap : Malignant Lymphoid Diseases
/
Dreyling, Martin (LMU Hospital (Alemanya)) ;
André, Marc (Université Catholique de Louvain (bèlgica)) ;
Gökbuget, Nicola (Goethe University (Alemanya)) ;
Tilly, Hervé (Centre Henri Becquerel and Université de Rouen (França)) ;
Jerkeman, Mats (Skåne University and Lund University (Suècia)) ;
Gribben, John (Queen Mary University of London (Regne Unit)) ;
Ferreri, Andrés (IRCCS San Raffaele Scientific Institute (Itàlia)) ;
Morel, Pierre (CHU Amiens Picardie (França)) ;
Stilgenbauer, Stephan (Universität Ulm (Alemanya)) ;
Fox, Christopher (University of Nottingham (Regne Unit)) ;
Maria Ribera, José (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Zweegman, Sonja (Amsterdam UMC (Països Baixos)) ;
Aurer, Igor (University of Zagreb (Zagreb)) ;
Bödör, Csaba (Semmelweis University (Hongria)) ;
Burkhardt, Birgit (Pädiatrische Hämatologie und Onkologie (Alemanya)) ;
Buske, Christian (University Hospital of Ulm (Alemanya)) ;
Dollores Caballero, Maria (El Instituto de Investigación Biomédica de Salamanca (Salamanca, Espanya)) ;
Campo, Elias (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Chapuy, Bjoern (Berlin Institute of Health (Alemanya)) ;
Davies, Andrew (University of Southampton (Regne Unit)) ;
de Leval, Laurence (Lausanne University Switzerland (Suïssa)) ;
Doorduijn, Jeanette (University Medical Center Rotterdam the Netherlands (Països Baixos)) ;
Federico, Massimo (GVM Care & Research (Itàlia)) ;
Gaulard, Philippe (Hôpital Henri Mondor (França)) ;
Gay, Francesca (AOU Città Della Salute e Della Scienza (Itàlia)) ;
Ghia, Paolo (IRCCS Ospedale San Raffaele (Itàlia)) ;
Grønbæk, Kirsten (University of Copenhagen (Dinamarca)) ;
Goldschmidt, Hartmut (University Hospital Heidelberg (Alemanya)) ;
Kersten, Marie-Jose (Cancer Center Amsterdam and LYMMCARE the Netherlands (Països Baixos)) ;
Kiesewetter, Barbara (Medical University of Vienna (Àustria)) ;
Landman-Parker, Judith (Sorbonne Université APHP/hôpital A Trousseau (França)) ;
Le Gouill, Steven (Clinique du Centre Hospitalier Universitaire (CHU) de Nantes (França)) ;
Lenz, Georg (Medical University Hospital Münster (Alemanya)) ;
Leppä, Sirpa (Helsinki University Hospital Comprehensive Cancer Centre Finland (Finlandia)) ;
López Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ;
Macintyre, Elizabeth (Assistance Publique-Hôpitaux de Paris (França)) ;
Mantega, Maria Victoria Mateos (Universidad de Salamanca (Salamanca, Espanya)) ;
Moreau, Philippe (University Hospital Hotel-Dieu (França)) ;
Moreno, Carol (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Nadel, Bertrand (Aix Marseille Univ (França)) ;
Okosun, Jessica (Queen Mary University of London (Regne Unit)) ;
Owen, Roger (St James's Institute of Oncology (Regne Unit)) ;
Pospisilova, Sarka (University Hospital Brno (Txèquia)) ;
Pott, Christiane (Universitätsklinikum Schleswig-Holstein (Alemanya)) ;
Robak, Tadeusz (Medical University of Lodz (Polònia)) ;
Spina, Michelle (National Cancer Institute (Itàlia)) ;
Stamatopoulos, Kostas (Centre for Research and Technology Hellas Greece (Grècia)) ;
Stary, Jan (Charles University Prague University Hospital Czech Republic (Txèquia)) ;
Tarte, Karin (Immunology and Cell Therapy Lab at Rennes University Hospital (França)) ;
Tedeschi, Allessandra (Niguarda Hospital Milano (Itàlia)) ;
Thieblemont, Catherine (Assistance Publique-Hôpitaux de Paris (França)) ;
Trappe, Ralf Ulrich (DIAKO Hospital Bremen (Alemanya)) ;
Trümper, Lorenz H. (University Medicine Goettingen (Alemanya)) ;
Salles, Gilles (Weill Cornell Medicine (Estats Units)) ;
Universitat Autònoma de Barcelona
2022 - 10.1097/HS9.0000000000000726
HemaSphere, Vol. 6 (may 2022)
|
|
|
10.
|
|
11 p, 1.4 MB |
Up to 8-year follow-up from RESONATE-2 : first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
/
Barr, Paul M. (Clinical Trials Office. Wilmot Cancer Institute. University of Rochester Medical Center) ;
Owen, Carolyn (Division of Hematology & Hematological Malignancies. Tom Baker Cancer Centre. University of Calgary) ;
Robak, Tadeusz (Medical University of Lodz) ;
Tedeschi, Alessandra (Department of Hematology. Azienda Socio Sanitaria Territoriali Grande Ospedale Metropolitano Niguarda) ;
Bairey, Osnat (Department of Hematology. Rabin Medical Center) ;
Burger, Jan A (Department of Leukemia. University of Texas MD Anderson Cancer Center) ;
Hillmen, Peter (Department of Haematology. The Leeds Teaching Hospitals. St. James Institute of Oncology) ;
Coutre, Steven E. (Stanford University School of Medicine. Stanford Cancer Cente) ;
Dearden, Claire (Haemato-Oncology Department. The Royal Marsden Hospital) ;
Grosicki, Sebastian (Department of Hematology and Cancer Prevention. School of Public Health. Silesian Medical University) ;
McCarthy, Helen (Royal Bournemouth General Hospital. Haematology Department) ;
Li, Jian-Yong (Jiangsu Province Hospital. Department of Hematology) ;
Offner, Fritz (Universitair Ziekenhuis Gent. Department of Clinical Hematology) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Zhou, Ccathy (Biostatistics. Pharmacyclics LLC. An AbbVie Company) ;
Hsu, Emily (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Szoke, Anita (Clinical Sciences. Pharmacyclics LLC. An AbbVie Company) ;
Kipps, Thomas J. (University of California San Diego. Department of Medicine. Moores Cancer Center) ;
Ghia, Paolo (Università Vita-Salute San Raffaele. Department of Onco-Hematology. Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele) ;
Universitat Autònoma de Barcelona
2022 - 10.1182/bloodadvances.2021006434
Blood advances, Vol. 6 Núm. 11 (june 2022) , p. 3440-3450
|
|
guest ::
email alert
or subscribe to the 
RSS feed.
